Chimeric Antigen Receptor Modified T Cells Infusion
Large B-Cell Lymphoma (LBCL)
N.N. Alexandrov National Cancer CentreCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Large B-Cell Lymphoma (LBCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Polatuzumab Vedotin Ruijin Hospital | Phase 3 | BB |
cc-5013 Ruijin Hospital | Phase 3 | B |
Zanubrutinib Ruijin Hospital | Phase 2 | B |
Decitabine Ruijin Hospital | Phase 2 | CCC |
cd19-ucart Zhejiang University | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →